Ren Hong, Wagner Abram L, Xie Jia-Yu, Chen Kai-Yun, Lu Yi-Han, Zheng Xu-Bin, Huang Tao, Boulton Matthew L, Chen Xiang-Xiang
Department of Viral Hepatitis Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Health Serv Insights. 2019 Dec 26;12:1178632919897276. doi: 10.1177/1178632919897276. eCollection 2019.
Low- and middle-income countries receive limited guidance from external entities about how to introduce vaccines. This is especially true for the Hepatitis E (HepE) vaccine, which is currently only commercially available in China. The aims of this qualitative study are to identify which attributes of the HepE disease and vaccine are considered important, and to compare desired promotion methods between different stakeholders. Stakeholders included experts (Centers for Disease Control and Prevention staff, health care providers, and researchers), and nonexperts included members of high-risk populations, HepE cases, and vaccinees. Participants' thoughts were coded and broadly summarized. We contacted 63 persons-35 experts and 28 nonexperts. Safety and effectiveness (but not price) of the vaccine, along with severity of disease and transmission route of infection, were all listed as important attributes. Emphasizing the importance of sharing stories from cases, relying on personal experiences, staying away from statistical explanations, and using the government as a source of promotion were other points repeatedly raised by the participants. Qualitative interviews with experts and nonexperts has revealed that focusing on attributes of disease severity and susceptibility to infection, as well as vaccine safety and effectiveness within stories of cases, are preferred ways to promote the vaccine.
低收入和中等收入国家在如何引进疫苗方面从外部机构获得的指导有限。对于戊型肝炎（HepE）疫苗来说尤其如此，该疫苗目前仅在中国有商业供应。这项定性研究的目的是确定戊型肝炎疾病和疫苗的哪些属性被认为是重要的，并比较不同利益相关者期望的推广方法。利益相关者包括专家（疾病控制与预防中心工作人员、医疗保健提供者和研究人员），非专家包括高危人群成员、戊型肝炎病例和疫苗接种者。对参与者的想法进行编码并进行大致总结。我们联系了63人——35名专家和28名非专家。疫苗的安全性和有效性（而非价格），以及疾病的严重程度和感染传播途径，都被列为重要属性。强调分享病例故事的重要性、依靠个人经历、避免使用统计解释以及将政府作为推广来源等也是参与者反复提到的要点。对专家和非专家的定性访谈表明，在病例故事中关注疾病严重程度和易感性属性，以及疫苗的安全性和有效性，是推广该疫苗的首选方式。
